Kidney transplant recipients vaccinated before transplantation maintain superior humoral response to SARS-CoV-2 vaccine


Posted: 2021-09-10 19:00:00
Clin Transplant . 2021 Sep 10;e14478. doi: 10.1111/ctr.14478. Online ahead of print. Ayelet Grupper 1 2 , Eugene Katchman 3 , Merav Ben-Yehoyada 4 , Liane Rabinowich 2 4 , Doron Schwartz 1 , Idit F Schwartz 1 , Moshe Shashar 5 , Tami Halperin 4 , Dan Turner 4 , Yaacov Goykhman 2 , Oren Shibolet 2 4 , Sharon Levy 2 4 , Inbal Houri 2 4 , Roni Baruch 1 2 , Helena Katchman 2 4 Affiliations Expand Affiliations 1 Nephrology department, Tel-Aviv Medical Center Tel-Aviv, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 2 Organ transplantation unit, Tel-Aviv Medical Center Tel-Aviv, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 3 Department of infectious diseases, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. 4 Liver Unit, Gastroenterology institute, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. 5 Nephrology section, Laniado Hospital, Netanya, Israel and Ruth and Bruce Rappoport Faculty of Medicine, Technion, Haifa, Israel. Item in Clipboard Ayelet Grupper et al. Clin Transplant. 2021. Show details Display options Display options Format Clin Transplant . 2021 Sep 10;e14478. doi: 10.1111/ctr.14478. Online ahead of print. Authors Ayelet Grupper 1 2 , Eugene Katchman 3 , Merav Ben-Yehoyada 4 , Liane Rabinowich 2 4 , Doron Schwartz 1 , Idit F Schwartz 1 , Moshe Shashar 5 , Tami Halperin 4 , Dan Turner 4 , Yaacov Goykhman 2 , Oren Shibolet 2 4 , Sharon Levy 2 4 , Inbal Houri 2 4 , Roni Baruch 1 2 , Helena Katchman 2 4 Affiliations 1 Nephrology department, Tel-Aviv Medical Center Tel-Aviv, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 2 Organ transplantation unit, Tel-Aviv Medical Center Tel-Aviv, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 3 Department of infectious diseases, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. 4 Liver Unit, Gastroenterology institute, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. 5 Nephrology section, Laniado Hospital, Netanya, Israel and Ruth and Bruce Rappoport Faculty of Medicine, Technion, Haifa, Israel. Item in Clipboard CiteDisplay options Display options Format Abstract Majority of transplant recipients did not develop an appreciable humoral response following SARS-CoV-2 vaccine, in contrast to dialysis patients and healthy individuals. We analyzed the serologic response to BNT162b2 (Pfizer-BioNTech) vaccine in a cohort of 19 kidney transplant recipients, vaccinated prior to transplantation, compare to 109 recipients vaccinated after transplantation, and to 39 healthcare workers, by determining the level of anti-spike antibodies after transplantation. All controls and 17 of 19 (90%) of recipients vaccinated before transplant were seropositive, while only 49 of 109 (45%) recipients vaccinated post-transplant had positive serology (p<0.001). Median anti-spike IgG in the group of kidney transplant recipients vaccinated after transplantation (10.7 AU/mL, (IQR 0-62.5)) was lower than the patients vaccinated before transplantation (66.2 AU/mL (21.6-138)), which was significantly lower than in the controls (156 AU/mL (99.7-215.5)). Negative humoral response was associated with vaccination post transplantation [odds ratio 22.4], older age [OR = 1.04], and longer time on dialysis [OR = 1.02], while higher lymphocyte count at time of vaccination was protective [OR = 0.52]. Our findings of sustained superior humoral response to SARS-CoV-2 vaccine in kidney transplant recipients vaccinated prior to transplantation strongly support the recommendations of SARS-CoV-2 vaccination of transplant candidates, especially those younger than 60 years. This article is protected by copyright. All rights reserved. Keywords: COVID-19; Kidney transplantation; SARS-CoV-2; vaccine. This article is protected by copyright. All rights reserved. [x] Cite Copy Format: Send To [x]

参考サイト PubMed: covid-19



バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
1月 29, 2021 バイオアソシエイツ

臍帯間葉系幹細胞による重度COVID-19治療で画期的な成果が報告された

マイアミ大学ミラー医学部の研究者らは、臍帯由来の間葉系幹細胞の注入によって最も重症の COVID-19 患者の死亡リスクを安全に減らし、回復までの時間を短縮することを示す、ユニークで画期的なランダム化比較試験を主導した。 STEM CELLS Translational Medicineで2021年1月5日に掲載されたこのオープンアクセス論文は「COVID-19急性呼吸窮迫症候群の臍帯間葉系幹細胞:二重盲検、フェーズ1 / 2a、ランダム化比較試験(Umbilical Cord Mesenchymal Stem…